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ABSTRACT
This consensus document provides an update for pathologists and clinicians about the interpretation of biopsy
results and use of this information in the management of hematopoietic cell transplantation patients. Optimal
sampling and tissue preparation are discussed. Minimal criteria for the diagnosis of graft-versus-host disease
(GVHD) are proposed, together with specific requirements for the diagnosis of chronic GVHD. Four final
diagnostic categories (no GVHD, possible GVHD, consistent with GVHD, and definite GVHD) reflect the
integration of histopathology with clinical, laboratory, and radiographic information. Finally, the Working Group
developed a set of worksheets to facilitate communication of clinical information to the interpreting pathologist and
to aid in clinicopathologic correlation studies. Forms are available at http://www.asbmt.org/cGvHD_Guidelines.
The recommendations of the Working Group represent a consensus opinion supplemented by evaluation of
available peer-reviewed literature. Consensus recommendations and suggested data-capture forms should be
validated in prospective clinicopathologic studies.
© 2006 American Society for Blood and Marrow Transplantation
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3NTRODUCTION
Histopathology has played a major role in under-
tanding the pathophysiology and aiding in the diagnosis
nd management of acute and chronic graft-versus-host
isease (GVHD). Historically, the clinicopathologic
lassiﬁcation of chronic GVHD was derived from a co-
ort of 20 patients in the late 1970s [1]. Many of these
arly cases were untreated or had disease that was refrac-
ory to the treatment that was available at the time.
escriptions and illustrations of fully developed histo-
ogic lesions of acute and chronic GVHD can be re-
iewed in several texts [2-7].
Even after 25 years since the initial publications of
he histopathology of progressive chronic GVHD,
any practical and unresolved issues in the surgical
athology of GVHD are not addressed in standard
exts. It is often not possible to distinguish persistent,
ecurrent, or late acute from chronic GVHD by his-
ologic examination. Furthermore, uniform minimal
iagnostic criteria for chronic GVHD have not been
stablished for affected organs, and histologic grading
ystems have not been validated in a prospective fash-
on. In retrospective studies, the degree of inﬂamma-
ion or the extent of epithelial damage or apoptosis has
ot predicted response to treatment in the gastroin-
estinal tract [3], skin [4], or liver [7,8].
Several factors can inﬂuence or cause difﬁculty in
istologic interpretation:
Potent immunosuppressive treatment blunts the
inﬂammatory response, one of the key indicators
of activity.
Infections and drug reactions can mimic chronic
GVHD.
Histologic characteristics change over time. Re-
sidual destruction of epithelia or glandular struc-
tures and irreversible ﬁbrosis pose problems in sep-
arating old damage from ongoing or new activity.
Sampling and technical factors can cause a false-
negative histologic assessment of GVHD.
The timing of biopsies and their relationship to
treatment are highly variable.
The utility of serial biopsies in judging the re-
sponse to treatment has not been determined.
To conduct clinical trials of chronic GVHD, uni-
ormly applied and interpreted criteria for pathologic
iagnosis are needed. These criteria should be validated
y multi-institutional studies with biopsies correlated
ith clinical information. Ideally, chronic GVHD trials
hould incorporate protocol-directed biopsies from
cheduled calendar- or event-driven collection proce-
ures to allow corollary histopathologic studies.
URPOSE
The purpose of this article is to provide an update for
athologists and clinicians about the interpretation of c
2iopsy results and use of this information in the man-
gement of hematopoietic cell transplant (HCT) pa-
ients. Speciﬁcally, the Working Group sought to (1)
eﬁne minimal diagnostic criteria for active GVHD in
everal organ systems, (2) deﬁne those features that sug-
est a speciﬁc diagnosis of chronic GVHD, (3) create a
tandardized terminology for communicating histology
esults, (4) distinguish active GVHD from previous ir-
eversible changes, (5) suggest the relevant clinical data
hat should accompany the biopsy, (6) deﬁne criteria for
n adequate histologic sample in various organs, and (7)
evelop comprehensive standardized research histo-
ogic data forms for reporting histologic changes. The
ecommendations of the Working Group represent
consensus opinion supplemented by evaluation of
vailable peer-reviewed literature. The proposed cri-
eria and terminology are provisional and will be up-
ated according to the results of prospective validation
tudies.
UMMARY OF RECOMMENDATIONS
Speciﬁc recommendations for sample acquisition,
assessment of adequacy of serial sections, and inter-
pretation are found in the text and Appendix 1.
Minimal diagnostic criteria for active GVHD and
features suggesting a speciﬁc diagnosis of chronic
GVHD are recommended.
All pathology reports should report both histologic
features and a ﬁnal diagnosis. The ﬁnal diagnosis
integrates the histopathologic results and the clini-
cal context and is summarized in 1 of 4 categories:
no GVHD, possible GVHD, consistent with
GVHD (equivalent to “favor,” “suggestive of,” or
“probable”), or deﬁnite, unequivocal GVHD.
Clinical information forms are provided for each
organ site. These forms are intended to improve
the ﬂow of relevant clinical information between
clinicians and pathologists. With institutional re-
view board approval, these forms can also be used
for research data collection in chronic GVHD
protocols.
ATIONALE FOR OBTAINING BIOPSY SAMPLES
Chronic GVHD has a prevalence of50% in long-
erm survivors after HCT. As detailed in the diagnosis
nd scoring article [9], biopsies are recommended to
onﬁrm active chronic GVHD in situations in which
nly distinctive clinical features of chronic GVHD are
resent, alternative diagnoses are entertained, clinical
igns are conﬁned to internal organs, or clinical assess-
ent is obscured by prior changes. In these instances,
istopathologic analysis should be viewed as essential for
stablishing activity, especially if there are any atypical
linical features, confounding infections, or potential
d
e
7
t
b
d
f
ﬁ
o
m
s
t
b
b
G
L
H
h
a
[
c
d
t
t
G
p
p
t
p
n
o
h
d
r
ﬂ
t
g
t
s
i
h
l
d
s
s
t
m
o
t
c
d
c
a
S
s
a
t
o
b
d
u
t
o
t
s
2
m
i
H
O
d
f
o
g
t
a
r
“
“
r
m
o
T
m
m
a
p
b
r
t
e
t
w
m
o
i
a
d
r
a
d
o
Histopathology of Chronic GVHD
Brug toxicity. Failure to obtain biopsies can result in
rroneous treatment. Jacobsohn et al. [10] found that
% of patients referred to Johns Hopkins for consul-
ation regarding chronic GVHD did not have biopsies
efore starting treatment and had been incorrectly
iagnosed and treated for active chronic GVHD be-
ore referral.
Although biopsy can be of enormous value in con-
rming the initial diagnosis of chronic GVHD, the role
f subsequent biopsies to assess the response to treat-
ent has not been determined. Also, the utility of
creening biopsies in asymptomatic patients who are still
aking immunosuppressive medications is controversial,
ecause asymptomatic patients with positive screening
iopsy results are not considered to have chronic
VHD.
IMITATIONS OF DIAGNOSING GVHD BY
ISTOPATHOLOGIC EXAMINATION
Whereas histologic features are purely descriptive,
istologic interpretation requires additional consider-
tion of the clinical context and the use of Bayesian logic
11]. Histopathology represents a snapshot in time of a
omplex and dynamic biologic process that reﬂects the
uration of activity, use of immunosuppressive therapy,
he possibility of more than 1 process, the location and
he quality of the sample, and the histologic preparation.
iven the high prevalence of chronic GVHD in the
opulation of interest, the positive predictive value of a
ositive biopsy for GVHD is high. The negative predic-
ive value of a biopsy, however, is less than the positive
redictive value [12]. As criteria for the minimal diag-
ostic threshold become more stringent, the sensitivity
f the biopsy to detect GVHD will decrease. As a result,
istologic examination may not always be the gold stan-
ard for the diagnosis of GVHD. Pathologists who are
eluctant to diagnose GVHD in biopsy samples without
orid abnormalities should understand that the decision
o treat GVHD is based not according to the histologic
old standard of a positive biopsy sample, but according
o the overall clinical assessment (see the gastrointestinal
ection, below). In research studies, patients can be strat-
ﬁed for analysis according to the presence or absence of
istologic changes.
Several factors can result in a false-negative histo-
ogic assessment of GVHD. Biopsies performed imme-
iately after the onset of symptoms and signs of pre-
umptive GVHD may be falsely negative. Tissue
ampling may be suboptimal. Biopsy of an oral or gas-
rointestinal ulcer rather than the adjacent intact mucosa
ay not show the changes of GVHD. Thin-needle bi-
psies of liver and poorly oriented gut biopsies can dis-
ort the relevant structures. Partial-thickness biopsies
annot be used to assess ﬁbrotic changes in the deep
ermis fat or fasciitis. Oral labial biopsies may not in- m
B&MTlude enough lobules of gland to differentiate between
ctive disease and previously damaged glandular tissue.
uboptimally processed and sectioned biopsies may ob-
cure key cytologic features. Glass slides containing only
limited number of serial sectionsmay be insufﬁcient for
he detection of focal minimal changes. GVHD may be
f mild intensity or may be partially or fully suppressed
y immunosuppression. In such cases, it is difﬁcult to
emonstrate that precise minimal diagnostic criteria are
niformly applied. An ongoing study of acute GVHD of
he skin between dermatopathologists at the University
f Washington and pathologists Fred Hutchinson bears
his out (D. Myerson, Fred Hutchinson Cancer Re-
earch Center, Seattle, WA, personal communication,
005). Conversely, a false-positive diagnosis of GVHD
ay result from concurrent infections, drug reactions, or
nﬂammatory reactions unrelated to GVHD.
ISTOLOGIC CRITERIA FOR THE MINIMAL DIAGNOSIS
F GVHD AND CHRONIC GVHD
Table 1 presents the minimal criteria necessary to
iagnose GVHD (whether acute or chronic) and the
eatures diagnostic for chronic GVHD in each involved
rgan system. When confronted with diagnostic ambi-
uity, pathologists respond by integrating the degree of
he histologic changes with available clinical details to
ssign some degree of certainty. The qualifying phrases
eﬂect both institutional and idiosyncratic preferences:
possible,” “probable,” “consistent with,” “suggestive” or
favor.” These are often coupled with additional terms
eﬂecting the extent of the changes: ie, “slight,” “mini-
al,” “mild,” “focal,” or “marked,” which convey a sense
f whether the changes are borderline or dramatic.
hus, criteria that suggest a diagnosis of GVHD or,
ore speciﬁcally, chronic GVHD are guidelines that
ay change with better knowledge of the clinical data
nd after the clinicopathologic results are known. Exam-
les of the inexact minimal criteria for GVHD in a
iopsy sample include the number of apoptotic bodies
equired in a skin, oral mucosal, or gastric biopsy sample
o diagnose GVHD; the number of hematoxylin and
osin (H&E) serial sections necessary before concluding
hat epithelial apoptosis is absent; the need for apoptosis
hen lymphocytic exocytosis is present in a skin or
ucosal biopsy sample taken immediately after the onset
f symptoms; the amount and location of inﬂammation
n the minor salivary glands required for the diagnosis;
nd the extent or degree of dysmorphic interlobular bile
uct changes that qualify portal inﬂammation as GVHD
ather than nonspeciﬁc reactive changes or alterations
scribed to hepatitis C virus (HCV) or a hepatotoxic
rug.
The pathology committee did not develop or rec-
mmend using any previously developed grading sche-
ata. Existing schemata are a composite of activity, gen-
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3rally assessed by inﬂammation or apoptosis, and
ccumulated damage or destruction, which reﬂects du-
ation (stage). Some schemata were developed without
esting data against useful clinical end points, and all are
trongly affected by the degree of immunosuppressive
reatment for GVHD. The sections below summarize
onsensus opinions.
iver
The diagnosis of liver GVHD is based on the global
ssessment of immune-mediated destructive damage to
mall bile ducts and ductules, together with cholestatic
nd inﬂammatory changes, after consideration of con-
ounding causes of liver disease from infection or drug
njury. Characteristic bile duct changes may be absent or
able 1. Histologic Criteria for GVHD by Organ System
rgan or System Minimal Criteria for Active GVHD*
kin, any stage Apoptoses in epidermal basal layer or lo
malphigian layer or outer root sheath
hair follicle or acrosyringium  licheno
inflammation  vacuolar change 
lymphocytic satellitosis
kin lichen
planus–like
kin sclerotic
kin morpheic
kin fasciitis
iver Global assessment of dysmorphic or
destroyed small bile ducts  cholestas
lobular and/or portal inflammation
astrointestinal Variable apoptotic criteria (>1/piece) in
crypts
ral mucosa and
conjunctiva
Lymphocytic infiltration of mucosa with
variable apoptosis‡
inor salivary or
lacrimal gland
ung
Conditions that result in lesser degrees of change include immunos
or small tissue sample, insufﬁcient serial sectioning, confoundin
Once the diagnosis of chronic GVHD has been established or af
disease may meet only minimal diagnostic criteria for activity.
Inﬂammation of the oral mucosa and within the minor salivary gla
distinction between acute and chronic GVHD requires the add
The distinction of past acinar destruction and ﬁbrosis from ongoi
that are not completely ﬁbrotic. Fibroplasia, with acinar and p
change, lymphocytic exocytosis, nuclear dropout, dyspolarity, o
Obliterative bronchiolitis [48] should be distinguished from bronch
GVHD but has a different clinicopathologic presentation and aay affect only a minority of portal spaces if the liver o
4iopsy is performed soon after the onset of liver dysfunc-
ion related to GVHD [13]. The duration of active liver
VHD, the anti-inﬂammatory effects of immunosup-
ression, and the anticholestatic inﬂuence of ursodeoxy-
holic acid affect these alterations.
There is no clear dichotomy between acute and
hronic GVHD in the liver. Long-term persistence of
VHD increases the amount of portal ﬁbrosis [13].
atients with acute hepatitis after donor lymphocyte
nfusions or tapering of immunosuppressive medications
ave more necroinﬂammatory activity and portal inﬂam-
ation than typically seen in patients who are receiving
mmunosuppression [8,14]. Liver biopsy samples vary
reatly in the number of portal spaces that can be eval-
ated. The greater the number, the more accurate the
Specific Criteria for Chronic GVHD†
Combination of epidermal orthorkeratosis, hypergranulosis,
and acanthosis with lichenoid changes  syringitis of
eccrine units  panniculitis
Collagenous deposition with thickening throughout the
papillary dermis, or pan-dermal collagenosis 
panniculitis
Clinically focal or localized lesion predominated by sclerosis
in the lower reticular dermis or along the
dermal-hypodermal border  epidermal and appendigeal
involvement
Fibrous thickening of fascial septa with adjacent
inflammation  panniculitis
Ductopenia, portal fibrosis, and chronic cholestasis reflect
chronicity but are not specific for chronic GVHD
Destruction of glands, ulceration, or submucosal fibrosis
refelects long-standing disease but are not specific for
chronic GVHD
Infiltration and damaged intralobular ducts, fibroplasia in
periductal stroma, and inflammation with destruction of
acinar tissue§
Obliterative bronchiolitis: dense eosinophilic scarring
beneath the respiratory epithelium, resulting in complete
fibrous obliteration or some degree of luminal narrowing
ive treatment, biopsy very soon after the onset of signs, suboptimal
tion, drug reaction, or inﬂammatory conditions.
unosuppressive treatment, the histologic manifestations of active
ay persist from prior chemoirradiation or prior inﬂammation. The
f distinctive oral manifestations [9].
nic GVHD activity can be difﬁcult and relies on assessing lobules
l inﬂammation and features of damage to ducts, such as vacuolar
osis, indicates chronic GVHD activity.
bliterans–organizing pneumonia [49], which is also associated with
favorable outcome.wer
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Histopathology of Chronic GVHD
Belies on a global assessment of characteristic withered
nterlobular bile ducts with nuclear and cytoplasmic al-
erations, with or without lymphocytic ductitis (Figure
). Although these changes may not be present in every
ortal space, they should be representative of the overall
icture. Unlike some other epithelia, apoptotic bile duct
hanges are infrequent.
Lymphocytic inﬁltration, nuclear and cytoplasmic
lterations, and proliferative ductular reactions along the
argins of portal spaces, previously described as bile
uctule proliferation (seeWeb link; liver worksheet), are
igure 1. Hepatic GVHD. A, Late onset of acute GVHD, day 123.
cattered eosinophils. The interlobular bile duct shows destructive
uclei, cytoplasmic vacuolization, and nuclear dyspolarity. Ductular
f GVHD (original magniﬁcation, 250). B, Refractory chronic
ppearance with dyspolarity, dropout of nuclei, nuclear enlarge
ytoplasm. The ﬁbrotic portal space contains scattered lymphoid c
ytoplasmic ballooning (original magniﬁcation, 250). C, Refra
uctopenia with a loss of bile ducts, a lymphoplasmacytic inﬁltrate, aimilar to those in affected interlobular bile ducts. The d
B&MTuctular reaction seems to represent both a reparative
ffort and a secondary target of GVHD. Data are insuf-
cient to determine whether quantitative immunohisto-
ogic assessment of bile duct loss by staining for cytoker-
tins 7 or 19 or replicative senescence by P21 staining
rovides additional information above and beyond the
sual histologic evaluation [15].
Refractoriness or a delay in starting treatment is
ssociated with greater loss of bile ducts and a longer
ime to recovery [8]. Refractory GVHD in the liver
sually produces a picture of chronic cholestasis with
panded portal space contains a mixed inﬁltrate of lymphocytes and
es of GVHD with inﬁltration by lymphocytes, segmental loss of
ration at the margins of the portal space also shows some features
, day 556. Interlobular bile ducts have a characteristic withered
anisonucleosis, inﬁltrating lymphocytes, and eosinophilia of the
d periportal hepatocytes show changes of chronic cholestasis with
ntreated chronic GVHD, day 350. Portal spaces have marked
osis with focal bridging (not shown; original magniﬁcation, 250).The ex
chang
prolife
GVHD
ment,
ells, an
ctory uuctopenia and, rarely, a picture of bile ductular prolif-
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3ration (reaction) with or without bridging ﬁbrosis
6,8,16]. In young pediatric patients with chronic liver
isorders, the developing hepatobiliary tract is especially
ulnerable to injury and prone to ﬁbrosis [17].
Although rare cases of cirrhosis have been attributed
o chronic GVHD [6,16,18], most were reported before
he identiﬁcation of HCV infection, which occurred in
p to 32% of patients who received HCT before the
dvent of blood-product screening for HCV [19]. Lon-
itudinal studies indicate that nearly all cases of cirrhosis
hat develop after HCT are caused by chronic HCV
20]. The long-term cumulative incidence of cirrhosis
rom HCV acquired after HCT is 24% at 20 years [21].
he usual manifestation of HCV is a mild self-limited
ncrease of serum aminotransferases during tapering of
mmunosuppression [19]. If no other signs of GVHD
re present, a liver biopsy may be necessary. Although
CV causes inﬂammation and reactive bile duct changes
6,13,22], the withered degenerative bile duct changes of
VHD are qualitatively different from those caused by
CV (Figure 1A and B).
Assessment of the response to therapy requires inte-
ration of the clinical and pathologic data, especially
ith liver biopsies, where improvement in liver tests and
istology may take months. The extent to which im-
rovement in clinical features correlates with repair and
egeneration of bile ducts is not known. In an anecdotal
ase with complete ductopenia, liver tests returned to
ormal after 1 year [8].
astrointestinal Tract
Upper esophageal webs are a diagnostic clinical fea-
ure of chronic GVHD [9]. In contrast, no histologic
hanges in the gastrointestinal tract are speciﬁc for
hronic GVHD. Features that reﬂect the duration of the
isease, ﬁbrosis within the lamina propria, crypt loss,
ymphocytic-plasmacytic inﬂammation, colonic Paneth
ell metaplasia, or submucosal or serosal ﬁbrosis are
equelae of refractory acute or late acute GVHD
2,3,7,23] (Figure 2).
Consensus as to whether clinical, endoscopic, or his-
ologic data deﬁne the gold standard for the diagnosis of
astrointestinal GVHD has not been reached. Large
iscrepancies can occur between gross endoscopic and
istologic ﬁndings [24]. Endoscopy can visualize the full
xtent of the changes, whereas biopsy is subject to the
igure 3. Progression of histologic changes from acute to chronic c
ormation is present at the tips of rete ridges (arrow) with focal surr
lanus–like chronic GVHD, day 426. The thickened epidermis displ
eaction along the damaged basal layer includes a prominent lymph
nd prominence of the superﬁcial vascularity (original magniﬁcation
82. A zone of dense, relatively avascular homogenized collagen has
63). D, High-power view shows a hyperkeratotic epidermis with ﬂ
long the basal layer, with disruption of the epidermal melanin un
elanin pigment in the sclerotic papillary dermis (original magniﬁcation,
6agaries of sampling and histologic preparation. When a
ut biopsy sample fails to show features of GVHD, the
robability of GVHD remains high in patients at risk
ho have typical signs and symptoms and gross endo-
copic appearance (mucosal edema) or ultrasound evi-
ence of mucosal edema, provided that all studies for
nfection are negative. After an extended discussion of
his issue between clinicians and pathologists, it was
ecommended that patients with only clinical evidence of
ut GVHD could be eligible for clinical trials, but that
igure 2. Gastrointestinal GVHD. A, Persistent GVHD in the
olon, day 87. The colonic biopsy specimen has numerous contig-
ous apoptotic changes (arrows; original magniﬁcation, 250). B,
ate acute GVHD in the stomach, day 133. The biopsy sample
hows pronounced lymphocytic and prominent eosinophilic inﬁl-
ration with destruction of gastric antral glands and formation of
rypt abscesses (original magniﬁcation, 250).
s GVHD. A, Screening skin biopsy, day 85. A focal apoptotic body
g lymphocytic satellitosis (original magniﬁcation, 400). B, Lichen
okeratosis, hypergranulosis, and acanthosis. The striking lichenoid
nﬂammation and inﬁltration, apoptotic changes, loss of rete ridges,
). C, Progression of GVHD from panel A into a sclerotic stage, day
ed the papillary and upper reticular dermis (original magniﬁcation,
g of the rete ridges, vacuolar changes, and lymphocytic inﬁltration
with coarse clumps of melanin in the epidermis and incontinentutaneou
oundin
ays orth
ocytic i
, 100
replac
attenin
it and160).
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3he analysis should be stratiﬁed according to presence or
bsence of histopathologic ﬁndings of GVHD.
The histologic threshold for a minimal diagnosis of
VHD in endoscopic biopsy samples was subject to
ome differences of opinion regarding any apoptosis ver-
us apoptosis in each piece. The histologic diagnostic
hreshold ranged from rare isolated apoptotic entero-
ytes to extensive lymphocytic inﬁltration with glandular
r crypt destruction and crypt abscesses ﬁlled with apo-
totic debris (apoptotic crypt abscess; Figure 2A). Eosin-
phils contribute to the injury, with variable scant to
eavy inﬁltration and destruction of glands with crypt
bscess formation (Figure 2B) [25]. Focally enhanced
astritis, characterized by small collections of lympho-
ytes, histiocytes with or without neutrophils surround-
ng small groups of foveolae or gastric glands, is found in
VHD and inﬂammatory bowel disease [26]. There was
ome disagreement about whether focally enhanced gas-
ritis should be regarded as “consistent with GVHD” in
he setting of HCT.
In the absence of confounding features (drug reac-
ion or infections), several variations of minimum criteria
hresholds requiring apoptotic enterocytes (excluding
hose on the surface) were suggested for a diagnosis of
consistent with GVHD”: at least 1 apoptotic body per
iopsy piece (University of Michigan), the total number
f apoptotic bodies at least to equal the number of pieces
FredHutchinsonCancer Research Center), or scattered
poptotic bodies in more than 1 crypt (M.D. Anderson).
one of these variations speciﬁes the number of serial
ections that should be cut and examined. Although this
ssue has not been formally studied, clearly false-negative
onclusions may result from examination of too few
erial sections. Because GVHD may have a patchy dis-
ribution with variable evidence of apoptosis, at least 8,
nd up to 20, serial sections should be analyzed to avoid
issing infrequent apoptotic changes or cytomegalovi-
us (CMV) viral inclusions. The use of apoptotic stains
eg, caspase 3) is neither recommended nor proven to be
ore useful than good-quality H&E serial sections.
The minimal diagnostic criteria are also subject to
alse-positive interpretation, because apoptosis in the gut
pithelium is not limited to GVHD. Cryptosporidia and
eavy CMV infection of the gut mucosa are well-known
auses of apoptosis [3,27]. Immunohistologic examina-
ion for CMV may be needed in selected cases to distin-
uish CMV from GVHD. Extensive apoptosis in the
bsence of identiﬁable CMV antigens by immunohistol-
gy is most likely to represent GVHD. Focal colonic
lcerations with marked apoptosis and acute and chronic
nﬂammation coupled with normal mucosal biopsy spec-
mens from sites distant from the lesions should raise the
ossibility of colitis due to mycophenolate mofetil expo-
ure [28]. Apoptosis has also been reported with the use
f proton pump inhibitors used to treat gastric disorders
29]. Small numbers of apoptotic changes in esophageal
ucosal biopsy specimens can arise from a variety of w
8hronic inﬂammatory conditions. Unless there is a com-
ination of lichenoid interface changes with apoptosis
long the basilar portion of the mucosa, the diagnosis of
sophageal GVHD should be made with some qualiﬁ-
ation (see “Standardized reporting of GVHD in the
Final Diagnosis’”).
With the exception of diffuse ulceration or ulcerated
tenotic segments veriﬁed by endoscopic or radiographic
valuations [30], it is unclear whether there is any addi-
ional prognostic value in the Lerner et al. [31] histologic
rading scheme for acute GVHD above and beyond
linical parameters. Some centers use the histologic
rading scheme routinely, whereas others do not. Any
roposed grading or staging scheme for gut GVHD
hould be a clinicopathologic composite score that re-
ects the overall extent of symptoms and damage seen by
ndoscopy and imaging studies, together with the degree
f histologic mucosal destruction or ﬁbrosis.
kin
The minimal histologic criteria for active GVHD
equire apoptosis within the basilar or lower spinosum
ayers of the epidermis (Figure 3A) [2,5,31]. The arche-
ypical features of both acute and chronic GVHD are
uperﬁcial interface dermatitis either (1) with a lichenoid
attern with lymphocytic inﬂammation with or without
ymphocyte satellitosis or (2) with predominately vacu-
lar change in the basilar layer [4,5]. As a note of caution,
ecause no single histologic feature is pathognomonic of
VHD, themajor overall inﬂammatory reaction pattern
hould be factored into the ﬁnal interpretation [32].
hus exuberant superﬁcial spongiotic dermatitis with
arked spongiosis (intraepidermal edema) and lympho-
ytic inﬁltration into the epidermis with only a rare
poptotic keratinocyte is much more likely to represent
n allergic reaction thanGVHD.The inconstant ﬁnding
f lymphocyte satellitosis (lymphocytes surrounding an
poptotic keratinocyte in the epidermis or appendages)
rovides evidence that the dermatitis is caused by
VHD.
The histologic manifestations of chronic cutaneous
VHD evolve over time, aremodiﬁed by treatment, and
o some extent overlap with those of acute GVHD. The
istologic counterparts to the proposed diagnostic clin-
cal deﬁnitions of cutaneous chronic GVHD include
everal different histologic patterns (Figure 3B). The
ichen-planus type eruptions (initially classiﬁed as early
eneralized extensive chronic GVHD [1,4]) refer to a
peciﬁc constellation with epidermal thickening by ac-
nthosis (hyperplasia) with orthokeratosis (stratum cor-
eum) and parakeratosis, hypergranulosis, a bandlike in-
ltrate along the dermal-epidermal junction, extensive
poptosis and vacuolization of basilar keratinocytes, saw-
oothed (short blunted) rete ridges, and inﬂammation
round the dermal adnexa. This constellation, especially
hen accompanied by lymphoplasmacytic inﬂammation
F
a
d
i
d
m
Bigure 4. Morpheic GVHD lesion, day 607. A, Low power shows a thickened dermis with sclerotic widening of the lower reticular dermis
nd fascia (original magniﬁcation, 20). B, The epidermis shows activity of GVHD with scattered apoptotic bodies. Note that the papillary
ermis is not sclerotic, in contrast to the deep dermis and fascia in panel D (original magniﬁcation, 400). C, Syringitis: eccrine coils are
nﬁltrated by lymphocytes with a loss of adjacent fat tissue replaced by ﬁbrous tissue (original magniﬁcation,200). D, Interface of the reticular
ermis and the fascia shows fasciitis with ﬁbrous thickening of the septa, lymphocytic panniculitis, and formation of lymphoid follicles (original
Histopathology of Chronic GVHDagniﬁcation, 63).
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4round the eccrine coils, is highly speciﬁc for chronic
VHD, but at the expense of reduced sensitivity. Be-
ause the skin lesions of chronic GVHD are not syn-
hronous, the presence or absence of chronic GVHD
eatures in a biopsy sample can be inﬂuenced by sam-
ling or partial thickness. In practice, members of the
ermatopathology subcommittee regarded the combina-
ion of epidermal compact orthokeratosis, hypergranu-
osis, and acanthosis as features that favor or are consis-
ent with chronic lichenoid GVHD (Figure 3). As a note
f caution, a lesser degree of this combination of features
an occur occasionally in skin biopsy specimens from
atients with severe clinical acute GVHD.
In the initial descriptions of sclerotic or late chronic
VHD, the ﬁbrosis that followed the lichenoid stage
ad a top-down progression from the papillary through
he reticular dermis (Figure 3C and D) [1,5]. Some
atients develop diffuse dermal sclerosis without an ap-
arent inﬂammatory lichenoid phase. The suggested
igure 5. Oral GVHD. A, Oral mucosal biopsy sample, day 75. T
original magniﬁcation, 160). B, High-powered view shows apop
400). C, Minor salivary gland, day 364. Early lobular involvement
issue (original magniﬁcation, 63). D, High-powered view of
acuolization, and focal destruction of the ductular epithelium (oriinimal criterion for the diagnosis of cutaneous sclerotic i
0hronic GVHD is homogenization (sclerosis) of most of
he papillary dermis or reticular dermis. In the morpheic
ariant of chronic cutaneous GVHD, sclerosis may be
argely conﬁned to the reticular dermis and underlying
ascia with little or no epidermal involvement. Another
ariant, fasciitis, may show ﬁbrous thickening only in the
ascia, with adjacent inﬂammation but without any epi-
ermal or dermal involvement [33] (Figure 4).
The cutaneous pathology group addressed the
hanges in chronic GVHD histologic characteristics as
elated to immunosuppressive treatment. After treat-
ent, skin biopsy samples display a combination of re-
idual damage, with loss of rete ridges and dermal ap-
endages, some increase in papillary or dermal sclerosis,
nd reduced to absent lichenoid inﬂammation. The hall-
ark of an incomplete response indicating ongoing
VHD activity is residual apoptotic changes in the epi-
ermis or appendages. After treatment, the histologic
igniﬁcance of minor residual perivascular lymphocytic
shows lymphocytic inﬁltrate along the basal layer of the mucosa
anges along the tip of a rete ridge (arrow; original magniﬁcation,
focal periductal lymphocytic inﬁltrates with minimal loss of acinar
alobular duct with marked lymphocytic inﬁltration, cytoplasmic
agniﬁcation, 160).his view
totic ch
shows
an intrnﬂammation or persistent epidermal vacuolar degener-
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Btion requires additional study, as does the assessment of
ctivity in patients who have received psoralen and
VA irradiation or who have established deep dermal
clerosis or morpheic chronic GVHD. The diagnosis
nd staging committee recommended that keratino-
yte apoptosis without other chronic GVHD features
n day 80 to 100 screening skin biopsy samples does
ot indicate chronic GVHD and does not necessarily
redict that a ﬂare may follow cessation of immuno-
uppressive therapy.
The cutaneous subgroup (E.F.) proposed a working
eﬁnition of marked apoptotic activity in the skin as 5
pidermal apoptotic bodies per section from a 4-mm
unch biopsy. Previous attempts to quantify the inﬂam-
atory changes of lichen planus–like chronic GVHD
id not correlate with the response to therapy, whereas
ontinued histologic signs of activity after treatment in-
reased the likelihood of some irreversible damage to
issues. Clinicopathologic correlation from prospectively
btained data will be used to evaluate these guidelines for
ssessing activity (see “Standardized reporting of GVHD
n the ‘Final Diagnosis’”).
ropharynx, Vulva, and Eye
On the basis of studies of oral labial biopsy samples
aken 80 to 100 days after HCT, patients without any
igns or biopsy evidence of GVHD may have chronic
nﬂammation without apoptotic changes in the mucosa
nd minor salivary glands. These changes were attrib-
ted to chemotherapy or irradiation in the conditioning
egimen [34]. Accordingly, lip biopsies to screen for
hronic GVHD were rarely performed before day 80.
ven so, some patients with aplasia who received only
yclophosphamide before HCT developed typical gross
hanges of oral chronic GVHD before day 80. A similar
ituation may also apply to reduced-intensity condition-
ng.
The minimal histologic criteria for oral chronic
VHD have remained unchanged: localized or gen-
ralized epithelial changes (lichenoid interface inﬂam-
ation, exocytosis, and apoptosis) similar to those
escribed in cutaneous GVHD or the presence of
ntralobular, periductal lymphocytes with or without
lasma cells and exocytosis of lymphocytes (without
eutrophils) into intralobular ducts and acini (Figure
). A later variation proposed the minimal criteria as
3 mucosal apoptotic bodies and, for salivary
hanges, a 10% loss of acinar tissue or ductal epi-
helial cell necrosis [35]. Periductal ﬁbrosis (not gen-
ralized interstitial ﬁbrosis) is often present. Horn et
l. [36] developed a histologic grading system for
hronic GVHD of minor salivary glands based on the
egree of lymphocytic inﬁltration and destruction of
landular acini. This GVHD grading schema and oth-
rs like it most accurately reﬂect the stage of the
isease. t
B&MTPersistent salivary dysfunction after treatment of
hronic GVHD is related to continuing lymphocytic
nﬂammation and absent recovery of minor salivary se-
retory units [37]. In children, oncocytic ductal metapla-
ia may be an additional feature favoring GVHD (T.
orton, University of Washington School of Dentistry,
eattle, WA, personal communication, 2005). Similar
ndings are commonly seen in oral biopsy specimens of
dults older than 40 years and are considered evidence of
revious ductal damage. Moderate to intense periductal
nd periacinar ﬁbroblastic stroma is evidence of previous
nﬂammation or chronic GVHD activity, whereas dense
brous tissue with destruction of acinal tissue and duct
ctasia may be only a marker for previous damage. The
ssessment of GVHD activity should focus on lobules
hat are not completely ﬁbrotic. In these nodules, ﬁbro-
lasia, acinar and periductal inﬂammation, and damage
o ducts indicate GVHD activity. Finally, clinicians and
athologist should be aware that premalignant dysplasias
nd oral cancers, a leading cause of secondary malignan-
ies after allogeneic transplantation, often present with a
ichenoid appearance [38,39].
The same criteria described previously for oral and
sophageal mucosa are used for histologic assessment of
hronic GVHD in vulvar [40], conjunctival, and lacrimal
iopsy specimens. Histopathologic ﬁndings of ocular
VHD have been described in the conjunctiva and in
he lacrimal gland [34,41-44]. The alterations in lacrimal
land acinar tissue resemble those in minor salivary
lands with prominent inﬁltration of mononuclear cells
round medium-size ducts, with loss of acinar lobules
eplaced by ﬁbrosis. Whereas lacrimal gland biopsy is
elatively invasive and may result in decreased functional
apacity, conjunctival biopsy samples may be obtained
ithout much risk to the patient. Histologic evaluation
f the conjunctiva may aid in the diagnosis and manage-
ent of ocular GVHD in symptomatic patients with
onjunctival disease [41,45,46]. Although the biopsy is
ot performed routinely, it may be particularly helpful
n cases in which ocular GVHD is in question in
ymptomatic patients who have normal or unchanged
chirmer tests with or without GVHD of other or-
ans. The conjunctival specimen may also be tested by
sing special stains for viral involvement when indi-
ated. Routine survey biopsy, however, is thought to
erve little beneﬁt for early detection of ocular GVHD
41,44]. Conjunctival histologic features for GVHD
nclude lymphocyte exocytosis, satellitosis, vacuoliza-
ion of the basal epithelium, and epithelial cell necro-
is, similar to changes that are observed in other or-
ans [41-45]. Other features are relatively nonspeciﬁc,
ncluding epithelial attenuation and goblet cell deple-
ion, which are not sufﬁcient for the diagnosis of
cular GVHD [43]. Corneal and conjunctival
seudomembranous histologic ﬁndings are clinical
anifestations generally associated with an acute pat-ern of ocular GVHD [45-47].
41
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4ungs
The pathologic ﬁnding of obliterative bronchioli-
is is considered to be a diagnostic feature of pulmo-
ary chronic GVHD and resembles chronic lung al-
ograft rejection [48]. Lung biopsy shows unequivocal
ense eosinophilic scarring of the bronchioles, result-
ng in some degree of luminal narrowing (Figure 6).
he process begins with inﬂammation around the
mall arteries and veins and beneath the respiratory
pithelial lining in small airways. Eventually, the sub-
ucosal layer is replaced by ﬁbrous tissue, and the lumen
s obliterated (also called constrictive bronchiolitis). Sec-
ndary changes include distal mucostasis or aggre-
ates of foamy macrophages. Inﬂammation is com-
on but variable and insufﬁcient for diagnosis. The
xtent and severity of changes should be correlated
ith functional studies, particularly if only a single
ffected airway is present in the biopsy specimen.
ther causes, such as infection and chronic aspiration,
hould be excluded [48]. Interstitial lung disease is not
onsidered to be a direct manifestation of GVHD. In
he presence of other distinctive organ features and
constellation of suggestive pulmonary function
ests and chest computed tomographic scans, a lung
iopsy is not necessary to diagnose pulmonary
hronic GVHD [9].
Idiopathic bronchiolitis obliterans–organizing pneu-
onia (BOOP) is associated with both acute and chronic
VHD. BOOP is a clinicopathologic syndrome deﬁned
y plugs of granulation tissue that ﬁll the lumens of the
istal airways in a patchy distribution, extending into
he alveolar ducts and alveolar sacs, and associated
ith chronic interstitial inﬂammation [49]. BOOP
hould be distinguished from obliterative bronchitis
ecause BOOP has a different clinicopathologic pre-
entation and a more favorable outcome.
ther Sites
Several other sites of chronic GVHD are less
ommonly involved or subjected to biopsy. Myositis is
learly a phenomenon associated with chronic GVHD.
comprehensive description with comparison to other
yositis entities has not been made. The skeletal mus-
le biopsy changes range from mild perimysial lym-
hocytic inﬁltrates to extensive endomysial inﬂamma-
ion with necrosis and regeneration of ﬁbers [1].
Biopsies may be useful in the evaluation of other
are manifestations that may be related to chronic
VHD. These syndromes include nephrotic syndrome
nd glomerulonephritis, inﬂammatory neuropathies, and
ynovitis. Chronic GVHD can cause obliterative coro-
ary artery changes that resemble transplant atheroscle-
osis. e
2TANDARDIZED REPORTING OF GVHD IN THE
FINAL DIAGNOSIS”
With this background, we propose terminology
hat can be used to qualify the certainty of a histologic
iagnosis of GVHD from any particular site (Table 2).
his schema allows the diagnosis to be expressed as a
ontinuum rather than “yes” or “no” and separates the
bjective histologic ﬁndings in the microscopic de-
cription from the subjective global interpretation.
or the diagnosis of GVHD, the 4 categories are the
ollowing: not GVHD, possible GVHD, consistent
ith GVHD (synonymous with probable, favor, or
uggestive), and GVHD (yes, without equivocation).
he pathologist should add these qualiﬁers, as needed,
n the ﬁnal diagnosis.
Of these categories, the most difﬁcult to deﬁne are
he qualiﬁed categories. A practical example involves
he long-standing controversy over whether GVHD
f the gut can be diagnosed in the presence of CMV.
Consistent with GVHD” in a gut biopsy sample with
nequivocal evidence of CMV would be appropriate if
here were abundant apoptotic epithelial changes not
ssociated with CMV-infected cells detected by im-
unostains, given that the 2 diagnoses are not mutu-
lly exclusive. Alternatively, if the pathologist believes
hat the changes can likely be ascribed only to CMV,
hen the diagnosis would be “no GVHD or possible
VHD” with a comment. “Consistent with GVHD”
pplies in the frequent situations in which a single or rare
poptotic change can be found without other accompa-
ying features. “Yes” is used when there is unequivocal
VHD with no further comment needed. The pathol-
gist may choose to use “GVHD with a comment”
hen the changes are atypical for chronic GVHD, or
igure 6. Pulmonary GVHD with obliterative bronchiolitis: lung
iopsy specimen, day 194. A small airway shows constriction of the
ronchiole lumen by a subepithelial expansion of ﬁbrous tissue. A
ymphocytic inﬁltrate surrounds the outer bronchiole smooth mus-
le layer (original magniﬁcation, 250; photo courtesy of Dr. Rob-
rt Hackman, of Fred Hutchinson Cancer Research Center).
“
l
s
s
(
p
D
P
r
s
c
t
t
o
p
a
i
o
s
o
m
s
l
c
p
r
t
n
f
T
N
P
C
G
M
T
L
G
C
Histopathology of Chronic GVHD
Bmarked” to indicate extensive destruction of epithe-
ium, ducts, or crypts, severe apoptosis of epithelia, or
evere inﬂammation. For example, with the skin work-
heet, the guideline recommended by Johns Hopkins
Evan Farmer) for marked epidermal apoptosis is 5
er section.
ATA COLLECTION AND COMMUNICATION BETWEEN
ATHOLOGISTS AND CLINICIANS
Standardized reporting of results can also advance
esearch related to chronic GVHD. In addition to
tandard information regarding the sample and pro-
essing, the Working Group recommends that all pa-
hology reports in which GVHD is questioned include
he following information: date of the transplantation
r the day after transplantation or after donor lym-
hocyte infusion, the question that the clinician is
sking or the reason for the biopsy, and other clinical
nformation as provided by the clinician. The pathol-
able 2. Recommendation for Final Diagnosis Categories
Category Definition
ot GVHD No evidence for GVHD
ossible GVHD Evidence of GVHD but other
possible explanations
● Ob
ne
● Fo
ap
cry
● Co
he
● Cli
a d
onsistent with
GVHD
Clear evidence of GVHD
with mitigating factors
● Un
ab
th
inf
● Sin
ch
ac
ex
● Lim
fin
● Re
ra
VHD Unequivocal evidence of
GVHD and no further
comment necessary
● Infl
ex
ep
MF indicates mycophenolate mofetil.gy report should mention of the adequacy of the
O
B&MTample. For small biopsy specimens of skin and for
ral and gastrointestinal mucosa biopsy samples, this
eans preferably 2 slides, each with 8 to 10 serial
ections. Within the microscopic description, histo-
ogic details should be provided. A ﬁnal diagnosis that
ombines the histologic and clinicopathologic inter-
retation should be provided according to the catego-
ies suggested in the relevant sections above.
Standardized methods of data collection can facili-
ate clinical interpretation, communication between cli-
icians and pathologists, and prospective data collection
or histopathology studies. The Working Group has
Examples Comments
MV enteritis with inclusions
apoptotic changes
Indicates possible alternate
diagnoses and reasons
for suspicion
nic ulcers with marked
cryptitis and destruction of
sociated with use of MMF
n with known active viral
atures that suggest or favor
action
cal evidence of CMV yet
apoptotic epithelial changes
ot associated with CMV-
ells by immunostaining
Equivalent to “probable,”
“favor,” or “suggestive
of” GVHD
rare apoptotic epithelial
ithout other features of
HD and no alternative
ons
ample or minimal or focal
emotherapy or
apy
tion may be minimal despite
destruction of the targeted
If extensive destruction of
epithelium, ducts, or
crypts or marked
inflammation, may note
“marked activity,” but
the features that define
“marked” activity have
not been prospectively
defined and are highly
dependent on the
degree of secondary
immunosuppressive
treatment
able 3. Forms Recommended for Use by Clinicians and Pathologists
Organ
Clinical
Information Form
Research
Histology Form
iver A B
astrointestinal tract C D
utaneous E Fvious C
ar the
cal colo
optotic
pts as
infectio
patitis
nical fe
rug re
equivo
undant
at are n
ected c
gle or
anges w
tive GV
planati
ited s
dings
cent ch
diother
amma
tensive
itheliaral G H
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4eveloped clinical information forms (Table 3) and re-
earch histopathology worksheets. Readers can obtain
hese forms with their respective accompanying clinical
nformation forms by accessing the American Society for
lood and Marrow Transplantation (ASBMT) Web site
http://www.asbmt.org/cGvHD_Guidelines).
LINICAL INFORMATION FORMS
Standardized forms that suggest relevant clinical
ata to accompany a biopsy have been developed. The
orms suggest a format for collection of such data as
he date and type of transplantation or donor lympho-
yte infusion, the reason for the biopsy and the differ-
ntial diagnosis, patient symptoms, and laboratory or
adiology test results (http://www.asbmt.org/cGvHD_
uidelines). In general, these forms allow clear com-
unication with the interpreting pathologist about
he patient’s clinical situation, potential comorbid
onditions that could affect the observed histology,
he clinician’s differential diagnosis (especially diag-
oses that require special testing, such as viral patho-
ens), and speciﬁc questions. The pathologist should
orm his or her initial histologic impression before
ntegrating all the clinical data.
These forms serve several purposes. First, they
ay accompany outside consultations to ensure that
he interpretation addresses the reasons for the biopsy.
n addition, the forms provide demographic trans-
lantation data and contact information for rapid
ommunication. Second, the forms could be used to
mprove clinical care within institutions by ensuring
hat pathologists have the relevant clinical data when
valuating a biopsy specimen. Finally, with appropriate
nstitutional review board approval, data collected on
hese forms could be used in histopathology research
tudies, in which standardized clinical and pathologic
ata are important.
We recognize many potential barriers to greater
se of these forms. It may be difﬁcult in a busy clinical
etting, hospital, or outpatient procedure room to
ocate and complete these forms. To improve access,
hese forms may be printed directly from the Web site
or use. Some institutions also require any forms used
or clinical care to be approved by a forms committee
ppointed by the institution. However, these forms
ould be appended to a standard pathology requisition
heet to facilitate communication of complete infor-
ation while minimizing interference with hospital
ocumentation requirements.
A sample cover letter requesting clinical informa-
ion and histologic material for outside consultations
s also presented on the ASBMT Web site: http://
ww.asbmt.org/cGvHD_Guidelines (form 1). All out-
ide consultants should include information indicating
ow to contact the attending clinician by e-mail, fax, and a
4elephone; the surgical pathology report; and, if possible,
he parafﬁn blocks or several unstained recuts. Properly
repared H&E-stained serial sections remain the pri-
ary source for diagnosing GVHD.
ESEARCH HISTOPATHOLOGY WORKSHEETS
The Working Group also developed standardized
ata collection research worksheets for liver, gut, skin,
nd oral/mucosal surface biopsy specimens. These work-
heets are available on the ASBMT Web site (http://
ww.asbmt.org/cGvHD_Guidelines). The worksheets
re intended not for daily diagnostic use, but rather
or guidance in the evaluation of the biopsy specimens
sed in clinicopathologic correlative studies when
aired with the clinical information forms discussed
reviously. The research histopathology forms are in
ilot testing to determine their suitability as commu-
ication tools. For example, study pathologists will
core the histologic changes in representative biopsy
amples that demonstrate the spectrum of minimal to
bvious GVHD, to test their understanding of the
eatures listed and determine the range of observa-
ions.
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PPENDIX 1: CONSIDERATIONS FOR SAMPLE
CQUISITION AND PROCESSING
iver Biopsies
Specimen. Needle biopsies (either percutaneous or
ransjugular) are recommended that use the widest
auge compatible with local clinical practice and
afety, with a total core length of at least 1.5 to 2 cm.
here should be at least 10 portal areas available for
valuation. If GVHD is a diagnostic consideration,
hen transvenous forceps biopsies are less desirable
ecause of the inevitable distortion of architecture.
hin-bore needle biopsies crush portal spaces and
istort bile ducts: if possible, they should be avoided.
Processing and Staining. Using the shorter 2-hour
rocessing schedule, especially with formalin-ﬁxed bi-
psy specimens, results in less shrinkage and improved
istology. If a portion of the biopsy specimen is to be
rozen, then this procedure should also be performed
s soon as possible after the biopsy is performed. If a
apidly progressing viral infection is clinically sus-
ected, then a portion should be sent for rapid shell
ial centrifugation culture. The clinician should advise
he pathologist regarding priorities for special studies.
Recommended routine and special stains include
&E, Masson trichrome, iron, periodic acid–Schiff
ith and without diastase, and reticulin for evaluation
f liver architecture. As needed, cytokeratin 19 (or
ytokeratin 7, if 19 is unavailable) may be used for
xamination of the biliary epithelium. Special stains
hould be obtained as indicated including copper or
all’s bile stain for cholestasis, ubiquitin, or P62 for p
B&MTvaluation of Mallory bodies in steatohepatitis, methe-
amine silver, and Kinyoun acid fast stains. Special
mmunostains for infectious agents include hepatitis B
urface and core antigens, adenovirus, herpes simplex,
erpes zoster, and CMV. Of note, liver involvement
ith CMV almost always occurs as part of a systemic
nfection, often coexisting with GVHD, and by itself
arely results in signiﬁcant liver dysfunction or icterus
30]. Additional immunostains for striking cellular in-
ltrations include lymphoid and/or myeloid antibod-
es, and antigens for the detection of posttransplant
ymphoproliferative syndrome, Epstein-Barr-encoded
NA, and latent membrane protein.
astrointestinal Biopsies
Specimen. A variety of institution-dependent sam-
ling strategies have been used: gastric antrum versus
undus versus duodenum. Discordance among clinical
everity, endoscopic observations, and biopsy ﬁndings
ay be observed. The most severely affected areas
ay not be sampled, particularly in the lower gastro-
ntestinal tract. It is important for the endoscopist to
ecord whether the biopsy represents a localized or
iffuse process.
Processing and Staining. Endoscopic biopsy speci-
ens must be properly oriented and placed directly
nto ﬁxative. At least 8 to 10 serial sections (recom-
ended 16-20) stained with H&E should be obtained
o detect minimal criteria changes for the diagnosis
f GVHD or rare viral inclusions. Special stains for
elicobacter species and viral infections should be ob-
ained as indicated.
kin Biopsies
Specimen. The gross appearance of the lesions and
he clinical context, whether for diagnosis or deter-
ining therapeutic response, dictate the type of bi-
psy. For most purposes, a 4-mm full-thickness punch
iopsy of lesional skin is sufﬁcient. If the patient is not
cutely ill, delaying the biopsy for a day or two will allow
he rash to become better developed and will avoid
quivocal histologic results (spongiosis and perivascular
nﬁltrate only). It is important to remember that cuta-
eous lesions are not synchronous. Concurrent biopsy
pecimens from several different sites may show classical
eatures of chronic GVHD in only 1 specimen. Certain
ypes of lesions are more difﬁcult to interpret. If the
kin is sclerotic or if fasciitis is suspected, a 6-mm
unch is better suited for assessment of deep involve-
ent of the hypodermis and the response to treat-
ent. Morpheic lesions also require larger and deeper
iopsy samples to appreciate the focal remodeling of
he dermis and changes in the deep fascia. In some
ituations, a combination of skin, oral, and mucosal
iopsies samples will be needed to assess the com-
leteness of the response.
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4Processing and Staining. Routine processing of for-
alin-ﬁxed material with at least 8 to 10 H&E-stained
erial sections, and preferably 16 to 20, is necessary.
everal studies have used immunostaining against T-cell
ubsets to discriminate GVHD from other non-GVHD
nﬂammatory dermatitides. In most biopsy samples with
VHD, the inﬁltrate is sparse. Furthermore, the phe-
otypic markers may not indicate a cell’s function.
tains for apoptosis, TUNEL, and anti–caspase-3 do
ot label cells that have the diagnostic appearance of
poptosis. At this time, these studies are not consid-
red appropriate for diagnostic use.
ral Mucosal and Lacrimal Biopsies
Specimen. An incisional biopsy (nonulcerated site
o include underlying gland lobules) with 5 to 10
obules is recommended. Mucosal and glandular dis-
ase may not be synchronous, and the disease may be
t various stages of development even in the lobules of
he gland removed at the same time in the same
pecimen.
Vulvar mucosal biopsy specimens are often sheared
ragments with a high background of nonspeciﬁc chronic
nﬂammation. Proper orientation of vulvar or conjunc-
ival mucosal biopsy samples is needed to evaluate the
eatures of GVHD.
For conjunctival and lacrimal biopsies, an incisional
iopsy (nonulcerated site to include underlying gland
obules) with 5 to 10 lobules is recommended. Mucosal
nd glandular disease may not be synchronous, and the
isease may be at various stages even in the lobules of the
land removed at the same time in the same specimen. A
onjunctival biopsy sample from the inferotemporal
ulbar conjunctiva is recommended. A snip biopsy
approximately 3 mm) specimen is usually sufﬁcient
o check for apoptotic cells in the conjunctival epithe-
ium.
Processing and Staining. Routine formalin ﬁxation
nd processing with serial sections are recommended.
pen Lung Biopsy
Specimen. Histologic evaluation for pulmonary
bliterative bronchiolitis cannot be performed with
ransbronchial biopsy or bronchoalveolar lavage spec-
mens. A diagnostic biopsy of pulmonary chronic
VHD requires evaluation of peripheral lung that
ontains bronchioles. The lung biopsy specimen, ob-
ained via a ﬁberoptic transthoracic or open thoracot-
my approach, should be at least 2 cm long.
Processing and Staining. To visualize the character-
stic concentric or eccentric submucosal collagenous
eposits beneath the epithelium that result in partial
o complete obliteration of the bronchiole lumen,
onnective tissue stains for elastica, Verehoeff van
ieson, or Movat are necessary [40].
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